Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.
about
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptorRecent advances in understanding multiple myelomaLong-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedDonor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.Bispecific antibodies engage T cells for antitumor immunotherapy.Use of tumour-responsive T cells as cancer treatment.Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maOrchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge.Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives.Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantationEffect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma.Cure of multiple myeloma -- more hype, less reality.Cellular therapy following allogeneic stem-cell transplantation.Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyComparison of twin and autologous transplants for multiple myeloma.CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.The allogeneic graft-versus-cancer effect.WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.Drug-mediated and cellular immunotherapy in multiple myeloma.Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment.Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies.Cellular immunotherapy for plasma cell myeloma.The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.Adoptive Cell Therapy in Multiple Myeloma.Immunologic approaches for the treatment of multiple myeloma.A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?The multi-faceted potential of CD38 antibody targeting in multiple myeloma.Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma.
P2860
Q24670205-83356A74-3ED8-4BC4-8EB8-0AFF1904399FQ28070331-08808D07-5065-4361-9C2F-CA7C06B04FAAQ30486842-D23D81B3-E745-43B6-95E4-834032A7D0ADQ33479917-207AD102-7D61-4141-ACD7-DAA7185663A5Q33691970-ADA89BFB-0102-4B99-8E43-78CBE9911B85Q34065058-0E19904A-4CA7-403B-96BB-6D4C4817D92AQ34124707-D611181D-548C-4809-8BBB-793E5B19B99DQ34174334-1A6847F6-70C7-4108-8B2A-4B29D17821AAQ34285656-268A326E-21AD-4B2F-845A-1D43809C886EQ34487409-79B6451E-E567-40F9-BEBC-9016147BEA6BQ34487436-FBA2E2D3-466D-40D6-A8FE-47042D10EF4AQ34808353-42056E8E-EE64-4AB3-9A52-5B7A7EBBCD1CQ35122185-BD9DD21A-9438-4429-A632-5D0314EB313CQ35605318-828561E1-2724-40CE-B4AE-B11BA0A57A59Q35783394-3E07ABA5-B29D-4EE0-83E5-200A4E1B8D13Q35884710-6460368D-2C38-4480-B4FB-6D57BA0E7284Q35891651-D92D7E2A-BA42-4FE9-9303-C599C56D63DCQ36013444-0593AFB9-58A2-4562-B573-16CB345A26ADQ36301128-E737ED49-0D06-4327-8D12-67DFFA0BC7A5Q36612643-BA4894AC-392C-4D62-B37E-3BF344F769A8Q36700598-845A3505-4135-42F0-84B6-BB1A28597CF2Q36834629-AB258C25-F25E-4AD9-A3B6-8AFFA86751F3Q36963203-B856B65A-2B61-419C-8864-C624BB0B7364Q36975837-EC2449A7-120E-418A-9A4E-8EF7E1296B18Q37155605-9C93A0A6-7462-4C6A-8188-694CD7CC2085Q37445265-E62FE0A0-60EE-46EB-9CA6-8D587C7E5681Q37593125-5967035E-C39F-4240-86B7-773811F22CF8Q37635023-6CF2EA41-5DF7-451A-BEE4-1D025035BC25Q37773257-C64B8BA9-340F-4E2A-86CE-B949BBCF3F05Q38042273-D41759CF-2F5E-42D9-A57F-E90114C9CD82Q38103578-439D78EF-B1EE-46E9-9134-F1CF4DD671C2Q38104288-F762D553-5FF7-4BF9-81F0-52A60A07440AQ38182679-8A186589-E946-4580-80A4-CFC6D22D66A9Q38417073-14ECDDC4-B2B9-4AF8-90A3-15981F05286CQ38532002-0286DD61-1E00-4F0A-A9B6-A3DF2A8E7933Q38635138-B44316BE-B756-4913-ACF1-8EC05381F840Q38692244-F9BCA3A7-4E62-4AC9-8461-64B5451B6048Q39112978-B99C9346-DC4A-4256-882F-1E0C01B0069FQ39200031-611BCFDD-4C2B-49A0-94A7-28BC4EE82A6FQ40342424-7CDA12C8-FE33-4800-9901-07A10BC515BA
P2860
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Donor lymphocyte infusions for ...... esponse and long-term outcome.
@en
type
label
Donor lymphocyte infusions for ...... esponse and long-term outcome.
@en
prefLabel
Donor lymphocyte infusions for ...... esponse and long-term outcome.
@en
P2093
P1476
Donor lymphocyte infusions for ...... esponse and long-term outcome.
@en
P2093
A Schattenberg
H M Lokhorst
J J Cornelissen
L F Verdonck
M H van Oers
P304
P356
10.1200/JCO.2000.18.16.3031
P407
P577
2000-08-01T00:00:00Z